Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 1
2020 1
2021 2
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer.
Csizmarik A, Keresztes D, Nagy N, Bracht T, Sitek B, Witzke K, Puhr M, Tornyi I, Lázár J, Takács L, Kramer G, Sevcenco S, Maj-Hes A, Jurányi Z, Hadaschik B, Nyirády P, Szarvas T. Csizmarik A, et al. Among authors: maj hes a. Int J Cancer. 2022 Oct 15;151(8):1405-1419. doi: 10.1002/ijc.34159. Epub 2022 Jun 21. Int J Cancer. 2022. PMID: 35689436 Free PMC article.
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer.
Csizmarik A, Nagy N, Keresztes D, Váradi M, Bracht T, Sitek B, Witzke K, Puhr M, Tornyi I, Lázár J, Takács L, Kramer G, Sevcenco S, Maj-Hes A, Hadaschik B, Nyirády P, Szarvas T. Csizmarik A, et al. Among authors: maj hes a. Prostate Cancer Prostatic Dis. 2023 Aug 26. doi: 10.1038/s41391-023-00713-y. Online ahead of print. Prostate Cancer Prostatic Dis. 2023. PMID: 37634036
Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial.
Mair MJ, Maj-Hes A, Nussbaumer-Pröll A, Puhr R, Christenheit A, Troch M, Puhr HC, Starzer AM, Steindl A, Eberl S, Haslacher H, Perkmann T, Minichsdorfer C, Prager GW, Lamm WW, Berghoff AS, Kiesewetter B, Zeitlinger M, Preusser M, Raderer M. Mair MJ, et al. Among authors: maj hes a. Infect Agent Cancer. 2023 Feb 12;18(1):9. doi: 10.1186/s13027-023-00487-x. Infect Agent Cancer. 2023. PMID: 36782325 Free PMC article.
Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer.
Szarvas T, Sevcenco S, Módos O, Keresztes D, Nyirády P, Csizmarik A, Ristl R, Puhr M, Hoffmann MJ, Niedworok C, Hadaschik B, Maj-Hes A, Shariat SF, Kramer G. Szarvas T, et al. Among authors: maj hes a. BJU Int. 2018 Oct;122(4):695-704. doi: 10.1111/bju.14415. Epub 2018 Jun 20. BJU Int. 2018. PMID: 29802777